{"schema_version":"secwatch.filing_event.v1","accession":"0001549595-25-000094","form_type":"8-K","ticker":"NRIX","cik":"0001549595","company_name":"Nurix Therapeutics, Inc.","filed_at":"2025-07-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.298526+00:00","generated_at":"2026-05-18T08:53:07.644082+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Nurix Q2 FY2025 revenue $44.1M (+264% YoY); Sanofi extends STAT6 license; bexobrutideg 80.9% ORR in CLL","bullets":["Revenue $44.1M (vs $12.1M YoY) driven by $30M Sanofi license extensions and $5M Gilead milestone.","Net loss $43.5M ($0.52/sh) vs $44.5M ($0.71/sh) prior year; cash $485.8M.","Sanofi extended STAT6 license for $15M payment; total $127M received; up to $465M in milestones remain.","Bexobrutideg Phase 1 data: 80.9% ORR in r/r CLL including a complete response; favorable safety (no AFib, fungal infections).","FDA cleared IND for IRAK4 degrader GS-6791/NX-0479; pivotal CLL trial for bexobrutideg expects to start H2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001549595-25-000094","json":"https://secwatch.observer/filing/0001549595-25-000094.json","markdown":"https://secwatch.observer/filing/0001549595-25-000094.md","text":"https://secwatch.observer/filing/0001549595-25-000094.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1549595/000154959525000094/0001549595-25-000094-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1549595/000154959525000094/nrix-20250709.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T08:53:07.644082+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}